New drug cocktail aims to shrink Hard-to-Treat sarcomas
NCT ID NCT04551430
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to the targeted therapy cabozantinib can shrink tumors better than cabozantinib alone in people with metastatic soft tissue sarcoma. About 105 adults whose cancer has worsened after prior treatments will participate. The main goal is to see how many patients have their tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOFT-TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, 19106, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune-boosting drug make chemotherapy more effective against sarcoma?
- New hope for sarcoma patients: drug slows tumor growth in late-stage trial
- Cancer drug shows promise in keeping sarcoma in check
- Lung-Directed chemo spray aims to stop cancer spread
- Immune cells take on sarcoma in early trial
- Experimental combo targets Hard-to-Treat sarcomas